China
The Australian side, in particular, can benefit by capitalising on its independent status to bring in more work from Western countries while still working with its former Chinese partner
King & Wood Mallesons will break into two entities, 14 years after a merger between a Chinese and an Australian firm created the combined outfit
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by Purplevine IPJoin Ude Lu, the chief IP counsel (US) of Purplevine IP, Helen Zhang, the litigation manager of Purplevine IP in Beijing, and Penny Sun, the brand protection manager of ABRO Industry, as they discuss evidence collection for patent enforcement in China and the US virtually with Managing IP on November 9 at 10am (US ET) / 3pm (UK) / 11pm (China) -
Sponsored by Wanhuida Intellectual PropertyXiaohui Wu of Wanhuida Intellectual Property reports on a ruling by the Supreme People’s Court of China that emphasises that the determination of common knowledge in the assessment of inventiveness should be incontrovertible
-
Sponsored by Liu, Shen & AssociatesAn increasing number of foreign companies are conducting research and development in China. Xuelan Yue of Liu Shen & Associates considers the implications and how to incentivise inventors
-
Sponsored by Liu, Shen & AssociatesDanchen Cheng of Liu Shen & Associates discusses the consequences of China’s amended patent law for partial design patent applications
-
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP analyses the Fifth Set of Listing Standards for Medical Device Companies on STAR Market of the Shanghai Stock Exchange, which encourages companies to develop core technologies
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
